Dr. Ian Flinn, chief scientific officer at Tennessee Oncology and One Oncology in Nashville, Tennessee, explains Lunsumio VELO (mosunetuzumab), a bispecific antibody, and its position in treating follicular lymphoma. Flinn describes how the therapy engages a affected person’s personal immune system to focus on cancerous B cells, providing a novel type of immunotherapy that may be given in a shorter, extra handy outpatient format.
Lunsumio VELO was lately granted accelerated approval by the U.S. Meals and Drug Administration (FDA). It really works by connecting two sorts of cells within the physique: B cells, which carry a marker known as CD20, and T cells, which have a marker known as CD3. By bringing these cells collectively, the therapy prompts the affected person’s T cells to acknowledge and destroy lymphoma cells. This method permits the immune system to immediately assault most cancers whereas serving to sufferers obtain focused remedy in a manageable, outpatient-friendly approach. It additionally gives clinicians with a remedy that may be delivered effectively whereas sustaining robust anti-cancer results, doubtlessly decreasing the general time sufferers spend within the clinic.
Transcript
Might you please clarify what Lunsumio VELO is and the way it works for sufferers with relapsed or refractory follicular lymphoma?
[Lunsumio VELO] is a bispecific antibody that targets an antigen on the floor of the lymphoma cells known as CD20, in addition to white blood cell lymphocytes. So if we take into consideration this slightly bit, if I provide you with a flu shot, you’ll develop an antibody that protects you in opposition to influenza. Within the laboratory, we are able to develop antibodies that focus on something we would like, together with CD20, which is expressed on lymphoma cells. These are historically known as bare antibodies. They’re unmodified. Right here, a bispecific antibody targets not solely the lymphoma cells, however it additionally targets white blood cells, on this case, lymphocytes that flow into in our blood, and it brings the lymphocyte to the lymphoma cell, the place the lymphocyte can then kill the lymphoma cells. And so it is a novel type of immunotherapy, or utilizing your individual immune system to combat the most cancers.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and training,
